These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

48 related articles for article (PubMed ID: 7534009)

  • 1. [Proliferative activity and defective replication in breast cancer].
    Kreipe H; Zeidler R; Kneitz H; Feist H
    Verh Dtsch Ges Pathol; 1994; 78():36-7. PubMed ID: 7534009
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Amplification of c-myc but not of c-erbB-2 is associated with high proliferative capacity in breast cancer.
    Kreipe H; Feist H; Fischer L; Felgner J; Heidorn K; Mettler L; Parwaresch R
    Cancer Res; 1993 Apr; 53(8):1956-61. PubMed ID: 8096798
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Correlation between p53, c-erbB-2, and topoisomerase II alpha expression, DNA ploidy, hormonal receptor status and proliferation in 356 node-negative breast carcinomas: prognostic implications.
    Rudolph P; Olsson H; Bonatz G; Ratjen V; Bolte H; Baldetorp B; Fernö M; Parwaresch R; Alm P
    J Pathol; 1999 Jan; 187(2):207-16. PubMed ID: 10365096
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Amplification of the TOP2A gene does not predict high levels of topoisomerase II alpha protein in human breast tumor samples.
    Mueller RE; Parkes RK; Andrulis I; O'Malley FP
    Genes Chromosomes Cancer; 2004 Apr; 39(4):288-97. PubMed ID: 14978790
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Concurrent overexpression of p53 and c-erbB-2 correlates with accelerated cycling and concomitant poor prognosis in node-negative breast cancer.
    Rudolph P; Alm P; Olsson H; Heidebrecht HJ; Fernö M; Baldetorp B; Parwaresch R
    Hum Pathol; 2001 Mar; 32(3):311-9. PubMed ID: 11274641
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Characterization of topoisomerase II alpha gene amplification and deletion in breast cancer.
    Järvinen TA; Tanner M; Bärlund M; Borg A; Isola J
    Genes Chromosomes Cancer; 1999 Oct; 26(2):142-50. PubMed ID: 10469452
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Topoisomerase IIalpha expression in breast cancer: correlation with outcome variables.
    Depowski PL; Rosenthal SI; Brien TP; Stylos S; Johnson RL; Ross JS
    Mod Pathol; 2000 May; 13(5):542-7. PubMed ID: 10824926
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mapping of DNA amplifications at 15 chromosomal localizations in 1875 breast tumors: definition of phenotypic groups.
    Courjal F; Cuny M; Simony-Lafontaine J; Louason G; Speiser P; Zeillinger R; Rodriguez C; Theillet C
    Cancer Res; 1997 Oct; 57(19):4360-7. PubMed ID: 9331099
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Amplification of HER-2/neu and topoisomerase IIalpha in primary and metastatic breast cancer.
    Tanner M; Järvinen P; Isola J
    Cancer Res; 2001 Jul; 61(14):5345-8. PubMed ID: 11454672
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Altered p16INK4 and retinoblastoma protein status in non-small cell lung cancer: potential synergistic effect with altered p53 protein on proliferative activity.
    Kinoshita I; Dosaka-Akita H; Mishina T; Akie K; Nishi M; Hiroumi H; Hommura F; Kawakami Y
    Cancer Res; 1996 Dec; 56(24):5557-62. PubMed ID: 8971152
    [TBL] [Abstract][Full Text] [Related]  

  • 11. p53 mutations and histological type of invasive breast carcinoma.
    Marchetti A; Buttitta F; Pellegrini S; Campani D; Diella F; Cecchetti D; Callahan R; Bistocchi M
    Cancer Res; 1993 Oct; 53(19):4665-9. PubMed ID: 8402644
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sporadic invasive breast carcinomas with medullary features display a basal-like phenotype: an immunohistochemical and gene amplification study.
    Rodríguez-Pinilla SM; Rodríguez-Gil Y; Moreno-Bueno G; Sarrió D; Martín-Guijarro Mdel C; Hernandez L; Palacios J
    Am J Surg Pathol; 2007 Apr; 31(4):501-8. PubMed ID: 17414096
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Proliferative activity and p53 expression in adenoid cystic carcinoma of the breast.
    Pastolero G; Hanna W; Zbieranowski I; Kahn HJ
    Mod Pathol; 1996 Mar; 9(3):215-9. PubMed ID: 8685217
    [TBL] [Abstract][Full Text] [Related]  

  • 14. DNA damage, c-myc suppression and apoptosis induced by the novel topoisomerase II inhibitor, salvicine, in human breast cancer MCF-7 cells.
    Lu HR; Meng LH; Huang M; Zhu H; Miao ZH; Ding J
    Cancer Chemother Pharmacol; 2005 Mar; 55(3):286-94. PubMed ID: 15592835
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparative polymerase chain reaction analysis of c-myc amplification on archival breast fine-needle aspiration materials.
    Rao JY; Apple SK; Jin Y; Lin S; Nieberg RK; Hirtschowitz SL
    Cancer Epidemiol Biomarkers Prev; 2000 Feb; 9(2):175-9. PubMed ID: 10698478
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mutated p53 protein expression and proliferative activity in advanced gastric cancer.
    Ikeguchi M; Saito H; Kondo A; Tsujitani S; Maeta M; Kaibara N
    Hepatogastroenterology; 1999; 46(28):2648-53. PubMed ID: 10522058
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Topoisomerase II alpha co-amplification with erbB2 in human primary breast cancer and breast cancer cell lines: relationship to m-AMSA and mitoxantrone sensitivity.
    Smith K; Houlbrook S; Greenall M; Carmichael J; Harris AL
    Oncogene; 1993 Apr; 8(4):933-8. PubMed ID: 8096076
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Estrogen receptor-negative and human epidermal growth factor receptor 2-negative breast cancer tissue have the highest Ki-67 labeling index and EGFR expression: gene amplification does not contribute to EGFR expression.
    Umemura S; Takekoshi S; Suzuki Y; Saitoh Y; Tokuda Y; Osamura RY
    Oncol Rep; 2005 Aug; 14(2):337-43. PubMed ID: 16012712
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Correlations among p53, Her-2/neu, and ras overexpression and aneuploidy by multiparameter flow cytometry in human breast cancer: evidence for a common phenotypic evolutionary pattern in infiltrating ductal carcinomas.
    Smith CA; Pollice AA; Gu LP; Brown KA; Singh SG; Janocko LE; Johnson R; Julian T; Hyams D; Wolmark N; Sweeney L; Silverman JF; Shackney SE
    Clin Cancer Res; 2000 Jan; 6(1):112-26. PubMed ID: 10656439
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunohistochemical characteristics defined by tissue microarray of hereditary breast cancer not attributable to BRCA1 or BRCA2 mutations: differences from breast carcinomas arising in BRCA1 and BRCA2 mutation carriers.
    Palacios J; Honrado E; Osorio A; Cazorla A; Sarrió D; Barroso A; Rodríguez S; Cigudosa JC; Diez O; Alonso C; Lerma E; Sánchez L; Rivas C; Benítez J
    Clin Cancer Res; 2003 Sep; 9(10 Pt 1):3606-14. PubMed ID: 14506147
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.